Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Ductal Carcinoma In Situ Treated With Mastectomy Using Vein-Mapping Guidance

Patient Info: Anonymized, Female, 60s

A 68-year-old woman with extensive ductal carcinoma in situ underwent mastectomy using a vein-visualization technique intended to reduce vascular injury during surgery.

PubMed CentralRead more →

Luminal A Breast Cancer Treated With Endocrine Therapy Before Partial Mastectomy

Patient Info: Anonymized, Female, 50s

Biomarkers: luminal A

A 56-year-old woman with luminal A invasive ductal breast cancer had marked tumor shrinkage after 3 months of endocrine therapy before partial mastectomy.

PubMed CentralRead more →

Stage IA invasive lobular breast cancer with ipsilateral marginal zone lymphoma: no recurrence after surgery and radiation

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Breast cancer was ER-positive, PR-negative, HER2-negative. Separate marginal zone lymphoma showed CD20/Bcl-2 markers

As of May 2025, five-month follow-up imaging showed no recurrence of the right breast invasive lobular carcinoma and no clinical recurrence of the ipsilateral marginal zone lymphoma.

PubMed CentralRead more →

Triple-negative sebaceous carcinoma of the breast: no recurrence after multimodality treatment

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative sebaceous breast carcinoma; EMA-positive; Ki-67 50-60%; inherited breast/ovarian cancer testing negative for pathogenic variants.

As of May 2025, after surgery, adjuvant chemotherapy, and radiation, she had 5 years of follow-up with no evidence of neoplastic recurrence.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Lauren's Survivor Story

Patient Info: Lauren Yerkes, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of May 2025, Lauren Yerkes was a triple-negative breast cancer survivor and founder of POST SWIM, a swimwear brand created from her post-mastectomy experience.

Breast Cancer: Honey's Survivor Story

Patient Info: Honey, Female

Honey completed surgical treatment for breast cancer with clear lymph nodes and margins. She declined radiation and chemotherapy, later stopped tamoxifen, and focused on recovery from surgical menopause symptoms and returning to art. No recurrence or metastatic disease was described.

The Patient StoryRead more →

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient StoryRead more →

Stage I Breast Cancer: Krista's Patient Story

Patient Info: Krista, Female | Stage I

Biomarkers: ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1

As of May 2025, Krista had undergone double mastectomy with flap reconstruction for Stage IA hormone receptor-positive, HER2-negative breast cancer and was taking tamoxifen with minimal early side effects.

The Patient StoryRead more →

Breast Cancer in a Woman Carrying Both BRCA1 and BRCA2 Mutations

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative, BRCA1 pathogenic variant, BRCA2 pathogenic variant

Remained free of recurrence 17 months after treatment.

PubMed CentralRead more →

Primary neuroendocrine breast tumor: disease-free 5 years after mastectomy and tamoxifen

Patient Info: Anonymized, Female, 50s

Biomarkers: Neuroendocrine breast tumor: ER/PR positive, HER2 negative

As of April 2025, she had remained disease-free for 5 years after mastectomy, negative sentinel lymph node biopsy, and tamoxifen 20 mg once daily.

PubMed CentralRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

Metaplastic triple-negative breast cancer: near-complete response to taxane/carboplatin before surgery

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated, triple negative

As of April 2025, imaging after taxane/carboplatin showed a near-complete morpho-metabolic response in the right breast and major reduction of axillary nodal disease, followed by surgery and adjuvant chemotherapy/radiotherapy.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Mandy's Patient Story

Patient Info: Mandy, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; low Oncotype score; genetic testing negative for 70 cancer-causing genes

As of April 2025, Mandy was about 10 months after bilateral mastectomy for Stage IA ER-positive, PR-positive ILC, had a low Oncotype score, was planning several years of tamoxifen, and was still in reconstruction.

Lobular Breast Cancer AllianceRead more →

Stage 0 Invasive Lobular Carcinoma: Kathleen's Survivor Story

Patient Info: Kathleen, Female | Stage 0

Kathleen completed surgery-focused treatment for DCIS with a very small invasive lobular component. No chemotherapy was needed, endocrine therapy was discussed but not required, and she continued imaging surveillance and advocacy in the flat community.

The Patient StoryRead more →

Breast cancer linked to a rare kidney condition believed to be cancer-related

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2 score 1+; Ki-67 5-10%

At the latest follow-up, she had no local or distant breast-cancer recurrence and maintained excellent performance status.

PubMed CentralRead more →

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed CentralRead more →

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed CentralRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →

HER2-Positive Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative, PR-negative, HER2-positive

Under surveillance with no evidence of breast-cancer recurrence for 2 years.

PubMed CentralRead more →

Ductal Carcinoma In Situ With Persistent Vaccine-Related Lymph Node Swelling

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive

Recovered uneventfully after mastectomy, with no additional cancer treatment given.

PubMed CentralRead more →

Bilateral inflammatory breast cancer treated with pembrolizumab and surgery

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Bilateral breast cancers had different biology: right side ER/PR-positive and HER2 FISH-negative; left side triple-negative/HER2 1+.

As of March 2025, she had no recurrence 6 months after bilateral mastectomy, bilateral axillary lymph node dissection, thoracoabdominal flap closure, and planned postmastectomy radiation for Stage IIIC bilateral inflammatory breast cancer.

PubMed CentralRead more →